{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:06:59Z","timestamp":1793765219507,"version":"4.6.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bronchiolitis obliterans syndrome (BOS) occurring after allogeneic hematopoietic cell transplantation (HCT) is a high-risk manifestation of chronic graft-versus-host disease. In this prospective, multicenter phase 2 trial, adult participants with BOS were treated with ruxolitinib 10\u00a0mg twice daily, continuously in 28-day cycles for up to 12 cycles. Participants enrolled into newly diagnosed (&amp;lt;6\u00a0months since BOS diagnosis, cohort A) or established (\u22656\u00a0months since BOS diagnosis, cohort B) disease cohorts. The primary objective was to evaluate the early treatment effect of ruxolitinib, assessed by the change in forced expiratory volume in 1 second (FEV1) at 3\u00a0months compared with enrollment. The primary end point differed according to cohort (cohort A, improvement, defined as \u226510% increase in FEV1; cohort B, stabilization, defined as an absence of \u226510% decrease in FEV1). Between 2019 and 2022, 49 participants meeting the criteria for BOS were enrolled and treated (cohort A, n\u00a0=\u00a036; cohort B, n\u00a0=\u00a013). The primary end point was achieved by 27.8% of participants with new BOS and 92.3% of participants with established BOS. According to the 2014 National Institutes of Health Consensus Criteria, the best lung-specific overall response rate on ruxoltinib for the 49 participants was 34.7% (16.3% complete response and 18.4% partial response), with most responses occurring in mild or moderate disease. Noninfectious severe (grade \u22653) treatment-emergent adverse events were infrequent. Nine severe infectious events occurred and were largely respiratory in nature. These results support the use of ruxolitinib in the management of BOS after allogeneic HCT. This trial was registered at www.ClinicalTrials.gov as #NCT03674047.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014000","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T17:06:18Z","timestamp":1728061578000},"page":"244-253","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"first","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[{"name":"2Department of Data Science, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-9634","authenticated-orcid":false,"given":"Guang-Shing","family":"Cheng","sequence":"additional","affiliation":[{"name":"3Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1252-6539","authenticated-orcid":false,"given":"Betty K.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Medical Oncology, Blood and Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karamjeet S.","family":"Sandhu","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Perez","sequence":"additional","affiliation":[{"name":"8Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Lee","sequence":"additional","affiliation":[{"name":"9Utah Transplant and Cellular Therapy Program, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy L.","family":"Brennan","sequence":"additional","affiliation":[{"name":"10Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Garrelts","sequence":"additional","affiliation":[{"name":"10Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bergin M.","family":"Brown","sequence":"additional","affiliation":[{"name":"10Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gallagher","sequence":"additional","affiliation":[{"name":"11Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-6961","authenticated-orcid":false,"given":"Richard A.","family":"Newcomb","sequence":"additional","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"26","key":"2025012813310523600_bib1","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"2025012813310523600_bib2","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2025012813310523600_bib3","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"issue":"20","key":"2025012813310523600_bib4","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2025012813310523600_bib5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood-2016-08-693507","article-title":"How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation","volume":"129","author":"Williams","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2025012813310523600_bib6","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbmt.2015.10.009","article-title":"Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation","volume":"22","author":"Williams","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2025012813310523600_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jca.21404","article-title":"Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation","volume":"31","author":"Brownback","year":"2016","journal-title":"J\u00a0Clin Apher"},{"issue":"6","key":"2025012813310523600_bib8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00408-017-0051-0","article-title":"Effect of rituximab on pulmonary function in bronchiolitis obliterans syndrome due to graft-versus-host-disease","volume":"195","author":"Brownback","year":"2017","journal-title":"Lung"},{"issue":"9","key":"2025012813310523600_bib9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jtct.2021.05.004","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2020 Treatment of Chronic GVHD Report","volume":"27","author":"DeFilipp","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2025012813310523600_bib10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jtct.2021.06.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2020 Highly Morbid Forms report","volume":"27","author":"Wolff","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2025012813310523600_bib11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/oncolo\/oyac076","article-title":"Recent FDA approvals in the treatment of graft-versus-host disease","volume":"27","author":"Martini","year":"2022","journal-title":"Oncol"},{"issue":"7","key":"2025012813310523600_bib12","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s41409-019-0450-3","article-title":"Ruxolitinib is an effective steroid sparing agent in children with steroid refractory\/dependent bronchiolitis obliterans syndrome after allogenic hematopoietic cell transplantation","volume":"54","author":"Schoettler","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2025012813310523600_bib13","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41409-019-0662-6","article-title":"Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease","volume":"55","author":"Streiler","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2025012813310523600_bib14","doi-asserted-by":"crossref","first-page":"668825","DOI":"10.3389\/fphar.2021.668825","article-title":"Salvage therapy with low-dose ruxolitinib leads to a significant improvement in bronchiolitis obliterans syndrome in patients with cGVHD after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025012813310523600_bib15","doi-asserted-by":"crossref","first-page":"916472","DOI":"10.3389\/fphar.2022.916472","article-title":"Ruxolitinib as an effective and steroid-sparing first-line treatment in newly diagnosed BOS patients after hematopoietic stem cell transplantation","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"3","key":"2025012813310523600_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025012813310523600_bib17","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1183\/09031936.00052806","article-title":"Bronchiolitis obliterans following haematopoietic stem cell transplantation","volume":"29","author":"Soubani","year":"2007","journal-title":"Eur Respir J"},{"issue":"15","key":"2025012813310523600_bib18","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/bloodadvances.2020002097","article-title":"The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"4","author":"Zeiser","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2025012813310523600_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2025012813310523600_bib20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/bmt.2012.241","article-title":"Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis","volume":"48","author":"Bergeron","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2025012813310523600_bib21","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease","volume":"8","author":"Lee","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2025012813310523600_bib22","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"2025012813310523600_bib23","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1182\/bloodadvances.2022008095","article-title":"Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials","volume":"6","author":"DeFilipp","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2025012813310523600_bib24","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1164\/rccm.201410-1818OC","article-title":"Budesonide\/formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation","volume":"191","author":"Bergeron","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"2025012813310523600_bib25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41409-022-01716-4","article-title":"The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial","volume":"57","author":"Matthaiou","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2025012813310523600_bib26","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study","volume":"41","author":"Kitko","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2025012813310523600_bib35","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"2025012813310523600_bib27","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1513\/AnnalsATS.201604-262OC","article-title":"Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant","volume":"13","author":"Cheng","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"2025012813310523600_bib28","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.bbmt.2019.12.002","article-title":"Early post-transplantation spirometry is associated with the development of bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation","volume":"26","author":"Jamani","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025012813310523600_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.exphem.2021.03.004","article-title":"Preclinical evaluation of JAK1\/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease","volume":"98","author":"Ryu","year":"2021","journal-title":"Exp Hematol"},{"issue":"8","key":"2025012813310523600_bib30","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/ajt.13750","article-title":"Proteomic characterization reveals that MMP-3 correlates with bronchiolitis obliterans syndrome following allogeneic hematopoietic cell and lung transplantation","volume":"16","author":"Liu","year":"2016","journal-title":"Am J Transplant"},{"issue":"1","key":"2025012813310523600_bib31","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/10428194.2017.1324155","article-title":"Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells","volume":"59","author":"Cheng","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2025012813310523600_bib32","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.3390\/ijms22136671","article-title":"VEGF regulation of angiogenic factors via inflammatory signaling in myeloproliferative neoplasms","volume":"22","author":"Suboticki","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2025012813310523600_bib33","doi-asserted-by":"crossref","first-page":"00185-2022","DOI":"10.1183\/23120541.00185-2022","article-title":"Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions","volume":"8","author":"Glanville","year":"2022","journal-title":"ERJ Open Res"},{"issue":"8","key":"2025012813310523600_bib34","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1111\/ajt.15814","article-title":"Multicenter evaluation of parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation","volume":"20","author":"Cheng","year":"2020","journal-title":"Am J Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/2\/244\/2351536\/blooda_adv-2024-014000-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/2\/244\/2351536\/blooda_adv-2024-014000-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T08:31:21Z","timestamp":1738053081000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/2\/244\/518046\/A-phase-2-multicenter-trial-of-ruxolitinib-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014000","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]}}}